BioAsset

Insights / All articles

FDA Approval

The FDA has approved Takeda’s oveporexton, the first orexin agonist for narcolepsy

By Joy Wu, Lead Analyst at BioAsset · 5 slides

The FDA has approved Takeda’s oveporexton, the first orexin agonist for narcolepsy.

Orexin is a brain signaling system that helps keep us awake and alert. Oveporexton works by restoring this signal in people with narcolepsy type 1.

The pharma world sees potential beyond a single narcolepsy treatment. Eli Lilly acquired Centessa for $7.8B+ to gain its experimental orexin drug. Orexin might also regulate attention, motivation and the brain’s reward system, and companies such as Alkermes are testing whether the same pathway can treat conditions such as ADHD and other neurological disorders. The opportunities mapped out for the orexin pathway run from sleep disorders and neuropsychiatry to neurodegeneration, addiction, and metabolic and cognitive health.

Morgan Stanley projects a potential $16B annual orexin market by 2035. On that view, the first approval signals a new neuroscience drug platform rather than a one-drug opportunity.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.